Skip to main content

Advertisement

Table 2 Hazard ratios (HRs) and 95 % confidence intervals (CIs) for different locations of fractures in the time-dependent model

From: Tamoxifen use reduces the risk of osteoporotic fractures in women with breast cancer in Asia: a nationwide population-based cohort study

Location Crude HR (95 % CI) p-value Adjusted HR (95 % CI) p-value
Overall       
Tamoxifen use (yes vs. no) 0.52 (0.45-0.61) <0.0001 0.59 (0.51-0.69) <0.00001
Increased dose of tamoxifen, per 100 DDD 0.98 (0.97-0.99) 0.0003 0.98 (0.97-0.99) 0.0002
Increased duration of tamoxifen use, per 100 days 0.98 (0.97-0.99) 0.0004 0.98 (0.97-0.99) 0.0002
Hip fracture       
Tamoxifen use (yes vs. no) 0.48 (0.39-0.57) <0.0001 0.55 (0.45-0.67) <0.0001
Increased dose of tamoxifen, per 100 DDD 0.97 (0.96-0.99) 0.0003 0.97 (0.96-0.99) 0.0005
Increased duration of tamoxifen use, per 100 days 0.98 (0.96-0.99) 0.001 0.97 (0.96-0.99) 0.0004
Vertebral fracture       
Tamoxifen use (yes vs. no) 0.59 (0.46-0.75) <0.0001 0.64 (0.50-0.82) 0.0003
Increased dose of tamoxifen, per 100 DDD 0.98 (0.97-1.00) 0.15 0.98 (0.97-1.00) 0.06
Increased duration of tamoxifen use, per 100 days 0.98 (0.97-1.00) 0.09 0.98 (0.97-1.00) 0.06
Wrist fracture       
Tamoxifen use (yes vs. no) 0.86 (0.43-1.71) 0.66 0.84 (0.42-1.68) 0.62
Increases dose of tamoxifen, per 100 DDD 1.01 (0.96-1.06) 0.83 1.01 (0.96-1.06) 0.76
Increased duration of tamoxifen use, per 100 days 1.01 (0.96-1.05) 0.83 1.01 (0.96-1.05) 0.86
  1. Manually adjusted for tamoxifen use, age, monthly income, comorbidity and aromatase inhibitor use before the end point
  2. DDD, defined daily dose